Cutaneous lupus erythematosus (CLE) may present as a clinically heterogeneous group of lupus-specific skin lesions that have common histopathological findings. Determination of the immunopathological sequence of events in this group of disorders has been challenging for dermatologists and immunologists but is vital for therapeutic targeting. We review animal models in which different aspects of immune alteration in CLE have been addressed. The MRL/lpr mouse develops spontaneous skin disease with some features of CLE. Study of this strain and related gene-manipulated strains has revealed roles for multiple cytokines, including interleukin (IL)-6, IL-18, and IL-21, in disease pathogenesis. A role for the growth factor colony stimulating factor 1 and the inflammatory protein high-mobility group box 1 has also been suggested. We discuss potential novel treatment options suggested by these models. Lupus (2010) 19, 1029—1035.
Crowson AN, Magro C.The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol2001; 28: 1-23.
3.
Lin JH, Dutz JP, Sontheimer RD, Werth VPPathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol2007; 33(1-2): 85-106.
4.
Furukawa F.Photosensitivity in cutaneous lupus erythematosus: lessons from mice and men . J Dermatol Sci2003; 33: 81-89.
5.
Cohen PL, Eisenberg RALpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol1991; 9: 243-269.
6.
Furukawa F., Tanaka H., Sekita K., Nakamura T., Horiguchi Y., Hamashima Y.Dermatopathological studies on skin lesions of MRL mice. Arch Dermatol Res1984; 276: 186-194.
7.
Furukawa F., Lyon MB, Norris DASusceptible cytotoxicity to ultraviolet B light in fibroblasts and keratinocytes cultured from autoimmune-prone MRL/Mp-lpr/lpr mice. Clin Immunol Immunopathol1989; 52: 460-472.
8.
Furukawa F., Kanauchi H., Wakita H., et al. Spontaneous autoimmune skin lesions of MRL/n mice: autoimmune disease-prone genetic background in relation to Fas-defect MRL/1pr mice. J Invest Dermatol1996; 107: 95-100.
9.
Licht R., Dieker JW, Jacobs CW, Tax WJ, Berden JHDecreased phagocytosis of apoptotic cells in diseased SLE mice. J Autoimmun2004; 22: 139-145.
10.
van Bavel CC, Dieker J., Muller S., et al. Apoptosis-associated acetylation on histone H2B is an epitope for lupus autoantibodies. Mol Immunol2009 ; 47: 511-516.
11.
O’Brien BA, Geng X., Orteu CH, et al. A deficiency in the in vivo clearance of apoptotic cells is a feature of the NOD mouse. J Autoimmun2006; 26: 104-115.
12.
O’Brien BA, Huang Y., Geng X., Dutz JP, Finegood DTPhagocytosis of apoptotic cells by macrophages from NOD mice is reduced. Diabetes2002; 51: 2481-2488.
13.
Korb LC, Ahearn JMC1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol1997; 158: 4525-4528.
14.
Eggleton P. , Ward FJ, Johnson S., et al. Fine specificity of autoantibodies to calreticulin: epitope mapping and characterization. Clin Exp Immunol2000; 120: 384-391.
15.
Taylor PR, Carugati A., Fadok VA, et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med2000; 192: 359-366.
16.
Trinder PK, Maeurer MJ, Schorlemmer HU, Loos M.Autoreactivity to mouse C1q in a murine model of SLE. Rheumatol Int1995; 15: 117-120.
17.
Napirei M., Karsunky H., Zevnik B., Stephan H., Mannherz HG, Moroy T.Features of systemic lupus erythematosus in DNase1deficient mice. Nat Genet2000; 25: 177-181.
18.
Yasutomo K. , Horiuchi T., Kagami S., et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet2001 ; 28: 313-314.
19.
N AG, Bensinger SJ, Hong C., et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity2009; 31: 245-258.
20.
Menke J., Hsu MY, Byrne KT, et al. Sunlight triggers cutaneous lupus through a CSF-1-dependent mechanism in MRL-Fas(lpr) mice. J Immunol2008; 181: 7367-7379.
21.
Popovic K., Ek M., Espinosa A., et al. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum2005; 52: 3639-3645.
22.
Urbonaviciute V., Furnrohr BG, Meister S., et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med2008.
23.
Jiang W., Pisetsky DSExpression of high mobility group protein 1 in the sera of patients and mice with systemic lupus erythematosus. Ann Rheum Dis2008; 67: 727-728.
24.
Barkauskaite V., Ek M., Popovic K., Harris HE, Wahren-Herlenius M., Nyberg F.Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus2007; 16: 794-802.
25.
Ulloa L., Ochani M., Yang H., et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A2002; 99: 12351-12356.
26.
Sawa H., Ueda T., Takeyama Y., et al. Blockade of high mobility group box-1 protein attenuates experimental severe acute pancreatitis. World J Gastroenterol2006; 12: 7666-7670.
27.
McHale JF, Harari OA, Marshall D., Haskard DOTNF-alpha and IL-1 sequentially induce endothelial ICAM-1 and VCAM-1 expression in MRL/lpr lupus-prone mice. J Immunol1999; 163: 3993-4000.
28.
McHale JF, Harari OA, Marshall D., Haskard DOVascular endothelial cell expression of ICAM-1 and VCAM-1 at the onset of eliciting contact hypersensitivity in mice: evidence for a dominant role of TNF-alpha. J Immunol1999; 162: 1648-1655.
29.
Norman MU, James WG, Hickey MJDifferential roles of ICAM-1 and VCAM-1 in leukocyte-endothelial cell interactions in skin and brain of MRL/faslpr mice. J Leukoc Biol2008; 84: 68-76.
30.
Pelton BK, Hylton W., Denman AMActivation of IL-6 production by UV irradiation of blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol1992; 89: 251-254.
31.
Wozniacka A. , Lesiak A., Boncela J., Smolarczyk K., McCauliffe DP, Sysa-Jedrzejowska A.The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVBirradiated skin in systemic lupus erythematosus. Br J Dermatol2008; 159: 1124-1130.
32.
Tang B., Matsuda T., Akira S., et al. Age-associated increase in interleukin 6 in MRL/lpr mice. Int Immunol1991; 3: 273-278.
33.
Parietti V. , Monneaux F., Decossas M., Muller S.Function of CD4+CD25+ Treg cells in MRL/lpr mice is compromised by intrinsic defects in antigen-presenting cells and effector T cells. Arthritis Rheum2008; 58: 1751-1761.
34.
Alarcon-Riquelme ME, Moller G., Fernandez C.Age-dependent responsiveness to interleukin-6 in B lymphocytes from a systemic lupus erythematosus-prone (NZB × NZW)F1 hybrid. Clin Immunol Immunopathol1992; 62: 264-269.
35.
Finck BK, Chan B., Wofsy D.Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest1994; 94: 585-591.
36.
Kinoshita K. , Yamagata T., Nozaki Y., et al. Blockade of IL-18 receptor signaling delays the onset of autoimmune disease in MRL-Faslpr mice. J Immunol2004; 173: 5312-5318.
37.
Wang D., Drenker M., Eiz-Vesper B., Werfel T., Wittmann M.Evidence for a pathogenetic role of interleukin-18 in cutaneous lupus erythematosus . Arthritis Rheum2008; 58: 3205-3215.
38.
Wuthrich RP , Jevnikar AM, Takei F., Glimcher LH, Kelley VEIntercellular adhesion molecule-1 (ICAM-1) expression is upregulated in autoimmune murine lupus nephritis. Am J Pathol1990; 136: 441-450.
39.
Meller S., Winterberg F., Gilliet M., et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: An amplification cycle triggering cutaneous lupus erythematosus . Arthritis Rheum2005; 52: 1504-1516.
40.
Wenzel J., Zahn S., Mikus S., Wiechert A., Bieber T., Tuting T.The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br J Dermatol2007; 157: 752-757.
41.
Hickey MJ, Bullard DC, Issekutz A., James WGLeukocyte-endothelial cell interactions are enhanced in dermal postcapillary venules of MRL/fas(lpr) (lupus-prone) mice: roles of P- and E-selectin. J Immunol2002; 168: 4728-4736.
42.
Mirolo M., Fabbri M., Sironi M., et al. Impact of the anti-inflammatory agent bindarit on the chemokinome: selective inhibition of the monocyte chemotactic proteins. Eur Cytokine Netw2008; 19: 119-122.
43.
Guglielmotti A., Aquilini L., D’Onofrio E., Rosignoli MT, Milanese C., Pinza M.Bindarit prolongs survival and reduces renal damage in NZB/W lupus mice. Clin Exp Rheumatol1998; 16: 149-154.
44.
Zoja C., Corna D., Benedetti G., et al. Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int1998; 53: 726-734.
45.
Preble OT, Rothko K., Klippel JH, Friedman RM, Johnston MIInterferon-induced 2'-5' adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon. J Exp Med1983; 157: 2140-2146.
46.
Reefman E., Kuiper H., Limburg PC, Kallenberg CG, Bijl M.Type I interferons are involved in the development of UVB-induced inflammatory skin lesions in systemic lupus erythematosus (SLE) patients. Ann Rheum Dis2008; 67: 11-18.
47.
McNiff JM, Kaplan DHPlasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus . J Cutan Pathol2008; 35: 452-456.
48.
Hida S., Ogasawara K., Sato K., et al. CD8+ T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity2000; 13: 643-655.
49.
Hron JD, Peng SLType I IFN protects against murine lupus. J Immunol2004; 173: 2134-2142.
50.
Yao Y., Richman L., Higgs BW, et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum2009; 60: 1785-1796.
51.
Sadanaga A., Nakashima H., Akahoshi M., et al. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice. Arthritis Rheum2007; 56: 1618-1628.
52.
Kalia S., Dutz JPNew concepts in antimalarial use and mode of action in dermatology. Dermatol Ther2007; 20: 160-174.
53.
Stetson DB, Ko JS, Heidmann T., Medzhitov R.Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell2008; 134: 587-598.
54.
Wenzel J., Uerlich M., Worrenkamper E., Freutel S., Bieber T., Tuting T.Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol2005; 153: 1011-1015.
55.
Peng SL, Madaio MP, Hayday AC, Craft J.Propagation and regulation of systemic autoimmunity by gammadelta T cells . J Immunol1996; 157: 5689-5698.
56.
Peng SL, McNiff JM, Madaio MP, et al. αβT cell regulation and CD40 ligand dependence in murine systemic autoimmunity. J Immunol1997; 158: 2464-2470.
57.
Kinoshita K. , Tesch G., Schwarting A., Maron R., Sharpe AH, Kelley VRCostimulation by B7-1 and B7-2 is required for autoimmune disease in MRL-Faslpr mice. J Immunol2000; 164: 6046-6056.
58.
Usmani N., Goodfield M.Efalizumab in the treatment of discoid lupus erythematosus. Arch Dermatol2007; 143: 873-877.
59.
Herber D., Brown TP, Liang S., Young DA, Collins M., Dunussi-Joannopoulos K.IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol2007; 178: 3822-3830.
60.
Espinosa A. , Dardalhon V., Brauner S., et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med2009; 206: 1661-1671.
61.
Chan O., Shlomchik MJA new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRLlpr/lpr mice. J Immunol1998; 160: 51-59.
62.
Kumar S., Benseler SM, Kirby-Allen M., Silverman EDB-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics2009; 123: e159-163.
